The AP1B1 Knockout HEK293T Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population targeting the AP1B1 gene in the HEK293T human cell background. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, resulting in a heterogeneous pool of edited cells that collectively abolish AP1B1 protein expression. The polyclonal format provides a robust population-level knockout system suitable for studying gene function without clonal selection biases. The product is designed for researchers investigating clathrin-mediated trafficking, lysosomal biology, and associated disorders, offering a versatile tool for endosomal pathway dissection.
HEK293T cells are derived from human embryonic kidney epithelium and have been immortalized through transformation with the SV40 large T antigen. This cell line is widely utilized in biomedical research due to its high transfection efficiency, rapid growth, and reliable protein expression capabilities. The epithelial origin and expression of SV40 large T antigen enable robust experimental manipulations, including transient and stable gene expression, making HEK293T a standard host for knockout studies. In the context of vesicular trafficking, HEK293T cells maintain an active endosomal-lysosomal system, providing a physiologically relevant platform for examining adaptor protein functions.
AP1B1 encodes the beta1 subunit of the adaptor protein complex 1 (AP-1), a heterotetrameric complex central to clathrin-dependent sorting at the trans-Golgi network (TGN). AP-1 is recruited to membranes by Arf1-GTP, a small GTPase of the Arf family, and interacts with clathrin, cargo receptors including mannose-6-phosphate receptors (M6PR), and accessory factors such as GGA1. The beta1 subunit specifically mediates interactions with clathrin and other AP-1 subunits (AP1G1, AP1M1, AP1S1), stabilizing the complex and facilitating vesicle formation. Downstream, AP-1?Cdependent trafficking directs lysosomal hydrolases to endosomes and has been implicated in synaptic vesicle component transport (VAMP2). Disruption of AP1B1 therefore impairs cargo sorting from the TGN, leading to mislocalization of lysosomal enzymes and altered endosomal composition.
In HEK293T cells, AP1B1 knockout provides a valuable model for dissecting TGN-to-endosome trafficking dynamics. These epithelial cells rely on clathrin-mediated pathways for receptor recycling, lysosomal enzyme delivery, and signal transduction. Loss of AP1B1 function is predicted to perturb the distribution of mannose-6-phosphate receptors and lysosomal hydrolases, potentially affecting lysosomal acidification and degradative capacity. The model is particularly relevant for studying MEDNIK syndrome, a neurocutaneous disorder caused by AP1S1 mutations that disrupt AP-1 complex assembly, highlighting the broader importance of AP-1 in neuronal and epithelial homeostasis. The polyclonal nature ensures that population-level phenotypes can be assessed without clonal artifacts.
This product supports a wide range of experimental applications, including trafficking pathway analysis through immunofluorescence co-localization of TGN markers (e.g., TGN46) with endosomal markers (EEA1), and functional assays such as transferrin uptake to assess clathrin-mediated endocytosis. M6PR trafficking assays and lysosomal enzyme activity measurements (e.g., cathepsin D) enable direct evaluation of sorting fidelity. Co-immunoprecipitation experiments with clathrin and ARF1, combined with Western blotting for AP-1 subunits, allow biochemical validation of complex disruption. RNA-seq transcriptomics can reveal compensatory transcriptional responses. The AP1B1 Knockout HEK293T Polyclonal Cells are thus a versatile resource for studying clathrin-dependent transport, lysosomal storage disorders, and drug targeting of vesicular pathways. For further details or technical support, please contact Ascent Research.
